Pfizer Inc.'s Pipeline Shrinks with Research Changes

AP -- The number of experimental drugs in human testing by Pfizer Inc. has shrunk by 12 percent over the past six months, mainly because the company has narrowed the areas in which it does research.
MORE ON THIS TOPIC